SELLAS Life Sciences (SLS) Non-Current Deferred Tax Liability (2015 - 2021)
SELLAS Life Sciences (SLS) reported Non-Current Deferred Tax Liability of $152000.0 for Q4 2021, down 36.4% year-over-year from $239000.0 in Q4 2020, and down 36.4% on a QoQ basis from $239000.0 in Q3 2021.
SELLAS Life Sciences (SLS) has 7 years of Non-Current Deferred Tax Liability data on file, last reported at $152000.0 in Q4 2021.
- Quarterly Non-Current Deferred Tax Liability fell 36.4% year-over-year to $152000.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $152000.0 (down 36.4% YoY) and the FY2021 annual result came in at $152000.0, down 36.4% from the prior year.
- Non-Current Deferred Tax Liability retreated to $152000.0 in Q4 2021 per SLS's latest filing, from $239000.0 in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $5.7 million in Q1 2017 and bottomed at $152000.0 in Q4 2021.
- The 5-year median for Non-Current Deferred Tax Liability is $357000.0 (2018), against an average of $1.4 million.
- The widest annual swing landed in 2017, when Non-Current Deferred Tax Liability grew 4.49%; it then plunged 79.27% in 2019.
- Tracing SLS's Non-Current Deferred Tax Liability over 5 years: stood at $1.7 million in 2017, then sank by 78.66% to $357000.0 in 2018, then fell by 26.61% to $262000.0 in 2019, then retreated by 8.78% to $239000.0 in 2020, then plunged by 36.4% to $152000.0 in 2021.
- Per Business Quant, the three latest SLS Non-Current Deferred Tax Liability figures stand at $152000.0 (Q4 2021), $239000.0 (Q3 2021), and $239000.0 (Q2 2021).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 152,000.00 |
| Dec 31, 2021 | 152,000.00 |
| Sep 30, 2021 | 239,000.00 |
| Sep 30, 2021 | 239,000.00 |
| Jun 30, 2021 | 239,000.00 |
| Jun 30, 2021 | 239,000.00 |
| Mar 31, 2021 | 239,000.00 |
| Mar 31, 2021 | 239,000.00 |
| Dec 31, 2020 | 239,000.00 |
| Dec 31, 2020 | 239,000.00 |
| Sep 30, 2020 | 262,000.00 |
| Sep 30, 2020 | 262,000.00 |
| Jun 30, 2020 | 262,000.00 |
| Jun 30, 2020 | 262,000.00 |
| Mar 31, 2020 | 262,000.00 |
| Mar 31, 2020 | 262,000.00 |
| Dec 31, 2019 | 262,000.00 |
| Dec 31, 2019 | 262,000.00 |
| Sep 30, 2019 | 357,000.00 |
| Sep 30, 2019 | 357,000.00 |
| Jun 30, 2019 | 357,000.00 |
| Jun 30, 2019 | 357,000.00 |
| Mar 31, 2019 | 357,000.00 |
| Mar 31, 2019 | 357,000.00 |
| Dec 31, 2018 | 357,000.00 |
| Dec 31, 2018 | 357,000.00 |
| Sep 30, 2018 | 1.72 Mn |
| Sep 30, 2018 | 1.72 Mn |
| Jun 30, 2018 | 1.72 Mn |
| Jun 30, 2018 | 1.72 Mn |
| Mar 31, 2018 | 1.67 Mn |
| Mar 31, 2018 | 1.67 Mn |
| Dec 31, 2017 | 1.67 Mn |
| Dec 31, 2017 | 1.67 Mn |
| Sep 30, 2017 | 5.66 Mn |
| Sep 30, 2017 | 5.66 Mn |
| Jun 30, 2017 | 5.66 Mn |
| Jun 30, 2017 | 5.66 Mn |
| Mar 31, 2017 | 5.66 Mn |
| Mar 31, 2017 | 5.66 Mn |
| Dec 31, 2016 | 5.66 Mn |
| Dec 31, 2016 | 5.66 Mn |
| Sep 30, 2016 | 5.42 Mn |
| Sep 30, 2016 | 5.42 Mn |
| Jun 30, 2016 | 5.42 Mn |
| Jun 30, 2016 | 5.42 Mn |
| Mar 31, 2016 | 5.42 Mn |
| Mar 31, 2016 | 5.42 Mn |
| Dec 31, 2015 | 5.42 Mn |
| Dec 31, 2015 | 5.42 Mn |